Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29983871 | 0.94 | BTK (0.58) | HPGDCTSKRECQLEPHX1HSD11B1 | |
| SCHEMBL15731609 | 0.91 | HSD11B1 (0.58) | HPGDCTSKRECQLEPHX1HSD11B1 | |
| SCHEMBL26478103 | 0.89 | HSD11B1 (0.48) | HPGDCTSKRECQLEPHX1HSD11B1 | |
| SCHEMBL4716377 | 0.87 | CHRNB2 (0.57) | HPGDCTSKRECQLEPHX1HSD11B1 | |
| SCHEMBL4713400 | 0.87 | HPGD (0.51) | HPGDCTSKRECQLEPHX1HSD11B1 | |
| SCHEMBL4711278 | 0.87 | CTSK (0.45) | HPGDCTSKRECQLEPHX1HSD11B1 | |
| SCHEMBL2296901 | 0.87 | RECQL (0.63) | HPGDCTSKRECQLHSD11B1CYP2C9 | |
| SCHEMBL1226780 | 0.87 | RECQL (0.63) | HPGDCTSKRECQLHSD11B1CYP2C9 | |
| SCHEMBL4716378 | 0.87 | CHRNB2 (0.57) | HPGDCTSKRECQLEPHX1HSD11B1 | |
| SCHEMBL4711280 | 0.87 | CTSK (0.45) | HPGDCTSKRECQLEPHX1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| EP-4313968-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022208269-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-10-06 | — | — | WO | disclosed |
| US-11365195-B2 | Atypical inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-06-21 | — | — | US | disclosed |
| US-11365195-B2 | Atypical inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210024523-A1 | ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024523-A1 | ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC18A2, SLC6A3, SLC6A4 | HPGD 3556/4885CTSK 2654/4885RECQL 2888/4885 |
| US-11365195-B2 | Atypical inhibitors of monoamine transporters; method of making; and use thereof | SLC18A2, SLC6A3, SLC6A4 | HPGD 3556/4885CTSK 2654/4885RECQL 2888/4885 |
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | HPGD 3097/4885CTSK 3577/4885RECQL 2767/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | HPGD 836/4885CTSK 2660/4885RECQL 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.